A critical appraisal and clinical application of Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742-748. doi: 10.1007/s10620-006-9312-0
Kane W. It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide. Clin. Res. Pract. 2016 July;2(2):eP1114.